(MedPage Today) — For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the risk of clinical worsening, the randomized HYPERION trial showed.
Among 320 patients, at least one primary…
Source link : https://www.medpagetoday.com/meetingcoverage/ers/117694
Author :
Publish date : 2025-09-30 07:22:00
Copyright for syndicated content belongs to the linked Source.
